We examined copy number changes in the genomes of B cells from 58 patients with chronic lymphocytic leukemia (CLL) using representational oligonucleotide microarray analysis (ROMA), a form of comparative genomic hybridization (CGH), at a resolution exceeding previously published studies. We observed at least one genomic lesion in each CLL sample and considerable variation in the number of abnormalities from case to case.
Introduction
Chronic lymphocytic leukemia (CLL), the most common form of adult onset leukemia in the western world, 1,2 is typically an indolent disease. While not all disease will progress to an advanced stage within the otherwise normal lifespan of the patient, CLL can evolve over time into a more dangerous and lethal disease. Patients who first present with CLL are usually not treated, as no statistically significant benefits from treatment in early stages of the disease have yet been demonstrated. Therefore, the ability to identify patients at greatest risk, i.e., those harboring lesions associated with poor prognosis, but who have not yet progressed, would offer an opportunity for selective and more effective therapy. Survival might be increased by treating patients with markers of advanced disease and sparing those not in need the toxic effects of therapy.
The heterogeniety of disease progression led to the Rai and Binet staging systems which remain the standard for tracking the disease and evaluating conditions for treatment. 3, 4 However, neither method can project the course of the disease in those patients diagnosed at early stages. Currently, several molecular markers, such as the presence or absence of IgVH somatic mutations, and expression of CD38 and 70-kDa zeta-associated protein (ZAP-70), appear to have prognostic value, 1,5-8 though each are limited in their ability to predict disease progression, survival, and resistance to therapy.
Improved prognosis might also be achievable by genome analysis. Cytogenetics, [9] [10] [11] fluorescent in situ hybridization (FISH), 12, 13 and comparative genome hybridization (CGH) 14 have revealed DNA segment gains (e.g., partial or complete trisomy 12) and deletions (e.g., 13q14.2, 11q22-q23, 17p13, and 6q21), which occur sporadically in CLL.
For personal use only. at COLD SPRING HARBOR LAB on October 15, 2008 . www.bloodjournal.org From Some of these loci correlate with prognostic outcomes, but to varying degrees. 10, 12, 15, 16 The sparcity of evidence linking these loci with specific genes indicates our incomplete understanding of the disease, and reflects the inadequacy of present tools for assessing chromosomal damage. We therefore conducted the present study with the aim of better describing the genomic abnormalities that occur in CLL, and to enhance the understanding of the ongoing evolution of genetic lesions in patients with CLL.
We began our initial study of the genomic landscape in close to sixty samples of CLL. We compared the leukemic genome to the patient's normal DNA using a high resolution CGH technique called representational oligonucleotide microarray analysis (ROMA). 17, 18 We designed oligonucleotide hybridization microarrays of 85,000 and 390,000 probes. On average, the resolution of the 85K and 390K arrays is a probe every 35kb and 9kb, respectively. In principle, each probe is a detector capable of measuring the relative "gene copy number" in a leukemic genome, however to infer true copy number changes with higher confidence we used no fewer than six consecutive probes.
The resolution of our study still exceeds previously published CGH studies on CLL. We have also examined some CLL samples at a resolution of 2.1 million probes to understand how the landscape changes when using an even-higher sensitivity In comparison to previous studies, we observed far more cases of CLL with lesions, and more lesions per case.
The resolution by ROMA is so high and the method is so sensitive that we can examine the clonal heterogeneity of CLL within the same patient from mixed subpopulations. The presence of greater than 30% of B-cells with the CD38 cell surface marker has been associated with poor outcome in CLL. 5 It is an open question whether Our studies indicate that complete analyses of genome stability and prognosis require high-resolution comparative genomic hybridization.
Patients and Methods

Patient Samples
The Institutional Review Board of the North Shore -LIJ Health System approved these studies. After obtaining informed consent in accordance with the Declaration of 
ROMA
We examined all CLL genomes with ROMA, a form of CGH that utilizes genomic representations. 18, 20 Complexity-reducing representations of genomic DNA were hybridized to microarrays of 50-mer oligonucleotide probes designed from the sequence of the human genome. 21 Samples were mainly hybridized on two platforms:
85K arrays based on Bgl II representations, and 390K arrays based on DpnII representations depleted of DpnII fragments containing AluI sites ("depleted" representations). 18 Array probes were chosen to be complementary to the complexityreduced representations. All arrays were manufactured by NimbleGen (NimbleGen, Madison, WI).
ROMA greatly increases signal-to-noise ratios in CGH, and diminishes the amount of sample needed for analysis. All hybridizations were performed in color reversal to prevent color bias and assure data quality. 22, 23 A few samples were hybridized without representation, and without color reversal, on NimbleGen's high-density, 2.1 million probe, prototype array (HD2). 
Informatics
Microarrays were scanned and gridded using GenePix Pro 4.0 software (MDS Analytical Technologies, Toronto, Canada) and data were imported into S-Plus 2000 analysis software (Insightful, Seattle, WA). The data were normalized using a lowess curve-fitting algorithm, followed by a local normalization (previously described in Hicks et al.). 20 After placement in genome order, the mean of log ratios was computed for color reversal experiments for each sample. All microarray data has been deposited with Gene
Expression Omnibus (GEO) under accession number GSE12794.
Segmentation was performed on the above-described data. Segments are defined as non-overlapping, genomic regions where copy number has changed. Our segmentation method is based on the minimization of "the square-sum of differences between log-ratios and means" (squared deviation) over segments larger than 4 probes in size. Initially, the segmenter searches for breakpoints that might be boundaries of segments. The first known breakpoint on a given chromosome is its first probe. For a given breakpoint, a 100-probe window to its right is selected. The sum of squared deviations of the flanking probes is calculated for each probe within this window. A probe whose squared deviation value produces a local minimum with respect to its neighbors, and is below a threshold of 95% of the square deviation within a window, is accepted as a new, known breakpoint. Whenever a probe is found below the threshold in for examples) to assure data quality.
Segmented data were further annotated with a script we developed to query a local UCSC hg18 database mirror to annotate segments for genome objects (i.e. genes, RNA genes, pathway information, gene ontology (GO) terms, etc), within, as well as spanning, breakpoints (not shown) to facilitate further data analysis.
Frequency plots were computed on the segmented data from 58 CLL samples hybridized to 390K arrays, using 1.1 and 0.9 (1/1.1) as upper and lower cut-off values ( Figure 5 ). A copy number variant (CNV) database based on our ROMA platforms was used to ensure the lesions observed in our dataset are not in fact CNVs. CNV frequencies were determined from a set of 500 profiles of cancer-free genomes, hybridized on the NimbleGen 85K array platform. 
Results
Strategic Approach
CLL cells and neutrophils (PMNs) were prepared from peripheral blood samples as described in Patients and Methods. We compared the respective DNAs, using patient PMNs as the normal genome. By comparing the CLL genome to the normal genome from the same patient, as opposed to an unrelated normal, we intrinsically avoid detecting copy number mutations that are frequent occurrences in the human gene pool, and that might otherwise be mistaken for recurrent genomic lesions in CLL.
Although we compare CLL to normal cells from the same person, it is still possible to confuse a copy number variation with a leukemic lesion because loss-ofheterozygosity (LOH) in the leukemia, such as arising by gene conversion, could unmask a heterozygous copy number variant present in the patient's germ-line. To guard against this, we also compared the PMN genome to an unrelated normal, by which method we can detect most germ-line copy number variants that could be unmasked by LOH.
Comparing PMN DNA to an unrelated normal also rules out a genomic abnormality arising in the PMN lineage (see, for example, Figure S1 ). Even this expedient, meant to avoid confusing copy number variation and leukemic lesions, fails when both patient, normal DNA and the DNA from an unrelated, normal control share the same copy number polymorphism. To further safeguard against this last source of error in interpretation, we further compared our results to a database of copy number variants derived from 500 normal humans (see, for example, Table S1 and Figure 5 ).
Most of our samples were analyzed on two platforms, 85K and 390K ROMA arrays. This has given us independent validation of variation seen at the 85K resolution (addressing false positives), and enabled us to reliably assess the value of increased resolution (addressing false negatives). For example, Figure 2 illustrates a deletion at
) in CLL 189 that is detected as a segment in the 390K data, but missed as a segment in the 85K data, although it is plainly present by visual inspection.
Our estimate of the false positive rate for the 85K array data is 3% (1/34) based on a discrepancy between events detected with the 85K array and not detected with the 390K array on identical samples. We do not have an independent estimate of the false positive rate for the 390K array data, but we have no reason to believe it is greater than that of the 85K array.
Detailed Summary of ROMA Data
The number of lesions detected in samples is highly variable (for example, see Figure 1 ). The leukemia sample CLL 334 of Figure 1 did not display any lesions at 390K (except of course for rearrangements at loci encoding immunoglobulins). However, even that sample displayed genomic lesions when analyzed on the 2.1 million high resolution array (see Figure S2 HD2 ).
Supplementary Table S2 (segmented data summary) and Table S1 (frequency plot summary) contain our summary of findings from hybridizations performed on 390K microarrays (58 CLL samples), including the boundaries of all leukemic events. We defined the minimal regions of overlap for all the recurrent lesions, determined their frequency and the number of genes therein, and compared them to the frequencies of known CNVs. We excluded from Table S1 rearrangements at the immunoglobulin loci but not for alpha (13q14.2) and beta (7q34) T-cell receptor (TCR) loci. TCR is known to recombine in malignant B-cells, though the mechanism permitting this is yet Figure 5 is a graphical representation of all the segmented data from the 58 profiles, including the immunoglobulin loci. Thus, the height at each locus reflects the number of times an event had been observed there. This figure also contains frequency plots of CNVs derived from a study of 500 normal humans. There was no significant overlap between the set of known CNVs and the genomic changes we observe in CLL.
With the exception of the deletion at 6q21, we observed all the previously reported major cytogenetic imbalances, and in many cases to a higher resolution than found in the literature. The majority of lesions (315/419) are deletions and not amplifications ( Figure 5 ), which is typical of CLL.
The common lesions include 11q, 13q, 17p deletions as well as trisomy 12.
Previously published reports observed the deletion at 6q21 in ~ 1.5-8% of samples.
12,27-31
Since we have sufficient probe coverage (roughly 1000 probes in the 9.1Mb region of 6q21), if this abnormality were present in our sample dataset, we would have observed it.
The lack of observance of this lesion is possibly due to sampling error.
There are eighteen (18) distinct regions where we have observed recurrent copy number mutations (duplications or deletions), two of them novel. ) and a 156kb region at 18q23 containing NFATC1 are particularly interesting.
In the case of NFATC1, the minimal region of overlap spans that single gene. Since breakpoints of both deletions and amplifications can disrupt the structure of a gene, we have analyzed all genes that span the breakpoints of deletions as well as amplifications. Genes were ranked according to how frequently breakpoints occur within them in all 58 samples (data not shown). Although no breakpoints were found within genes of known clinical significance (i.e. ATM, TP53, miR-15a/16-1), they were found to occur within genes flanking them. Furthermore, breakpoints were also frequently found in or near areas of segmental duplications.
Comparing ROMA to Classical Cytogenetics
The power of ROMA is further illustrated by its overall ability to detect lesions. Table S2 ). Previous claims of smallest observed lesions using CGH on CLL were 18 kb on a 644 probe BAC/PAC array and 70 kb on a 44K oligonucleotide array. 33, 37 These groups however, resorted to two (2) probe confidence intervals to make these claims, whereas we use four (4), giving us much higher confidence in our calls.
As might be expected, using a still-higher resolution platform could reveal additional lesions, too fine to be observed with current generation technologies. To explore this, we hybridized our most stable CLL genome (see Figure 1 , CLL334) to a high-density, 2.1 million probe, prototype array (HD2). CLL334 exhibited no discernible Figure S2) .
Clonal cell population analysis (CD38)
Elevated numbers of CD38 + cells within a CLL patient's B-cell population have been associated with poor prognosis. 5 It is as yet unclear whether the CD38 + cells arise from genetically distinct subpopulations of the CLL clone. To test this, we analyzed separated CD38 + and CD38 -fractions of four CLL samples. Copy number differences were detected in 3/4 samples ( Figure 3 and Table 2 ) at various loci throughout the genome, some of which are of clinical relevance (i.e. ATM and TP53). Since we assayed CD38 +/-fractions in a small number of samples, conclusions cannot yet be drawn on the role of certain loci in generating this diversity. However, we have clearly provided evidence of continuing genetic evolution in the CLL clones of some patients, and such continuing evolution may be related to disease outcome.
Discussion
In recent years, CGH has emerged as a powerful tool for detecting chromosomal duplications and deletions at a greater resolution than cytogenetics. Classical cytogenetics has identified gross regions of genomic instability in CLL, e.g. the common lesions, del 13q14.3, trisomy 12, del 11q22.3-23.2, and del 17p13.1. Enhanced cytogenetic techniques, such as refined G-banding, led to the narrowing of these
11,14 CGH can detect novel lesions, ascertain the frequencies of gains and losses with greater accuracy, and pinpoint candidate genes associated with the disease within known regions of recurrent abnormality. [33] [34] [35] [37] [38] [39] Therefore, based on previous experiences, 14, 40, 41 it was reasonable to expect that increased resolution would yield more accurate delineation of previously described lesions, as well as identification of new ones.
We used a high-resolution CGH to study CLL in order to consolidate existing knowledge of its genetics and to offer new insights into the nature of the disease.
However, there is a danger to the application of high resolution CGH techniques.
Previous comparative studies, performed at lower resolution, have ignored the issue of normal variation in the human genome. This is dangerous because at the scale we used to scan CLL the human genome is teeming with copy number variations. 24, 42 We took several precautions to guard against this. First and foremost we compared the CLL genome to the normal genome from the same patient. Additional steps to guard against mistaking a genome copy number change in CLL with a copy number polymorphism are described in "Strategic Approach" and the discussion of Figure 5 in the "Results" section.
Our results with high resolution arrays validated all but one of the previous set of known CLL genomic lesions. We confirmed that even at high resolution deletions are more abundant than amplifications. Previous studies report lesions in about 80% of cases, [33] [34] [35] 39 but we observed genomic lesions in all CLL samples. We saw lesions at most known loci at higher resolution than before, for example further delineating the complex epicenter of the highly recurrent deletion on 13q and shortening the list of candidate genes at other loci (see Table 1 ). Although, the smallest lesion we observe at the 13q region is 60kb in size, the minimal region of overlap from the frequency plot is (Figure 4 ). This observation suggests even greater complexity of lesions in the 13q region.
Additionally, we saw two recurrent lesions at new loci 2q37.1 and 8p21.2-p12, and many more genomic lesions at loci that were not recurrent. Our results suggest that the diversity of genomic aberrations in CLL is much greater than previously appreciated.
We used both a 390K array and an 85K array on most of our samples. By and large, the data sets agreed, but the 390K data showed somewhat more events (Figure 2 ). Still higher levels of resolution are now possible, and so we hybridized a limited number of patient samples (5) utilizing our HD2 prototype array with 2.1 million probes, seeking to ascertain whether additional lesions could be observed. One of the patients studied, CLL334, exhibited no discernible lesions by either 85K or 390K analyses, other than rearrangements at IGKC and IGH (Figure 1 ). However using the HD2 array, vastly more detail was observed, even at previously reported loci (see Figure S2 for one such example). We envision future studies utilizing HD2 will aid in narrowing down lesion breakpoints as well as uncovering many novel lesions that we did not observe with the 85K or 390K CGH platforms.
The amplitude of copy number changes (as observed in our figures) in CLL is often small, suggesting intraclonal heterogeneity. We estimate from doping experiments that we can observe lesions present in a minimum 30% of the total cell population. To find clearer evidence of intraclonal heterogeneity within patients, we looked for genomic differences between CD38 + and CD38 -populations in the same patient. We chose the CD38 activation marker as CLL can differ in the proportion of cells expressing CD38, and patients with ≥30% CD38 + cells have an unfavorable prognosis. 5, 7 If subclones within a patient harbor different genetic lesions and they have different proportions of cells expressing the CD38 marker at any given point in time, then we expect to observe these genomic differences by comparing CD38 + and CD38 -fractions. Indeed, we observed copy number differences between CD38 + and CD38 -fractions in three out of four cases (Figure 3) . Since the CD38 marker may be transiently expressed, 43, 44 our observation suggests that subclones of CLL spend differing amounts of time in the activated CD38 + state, compared to other clonal members that may be
This type of analysis enabled us to "time" the occurrence of events, as events not shared between two populations must occur subsequently to their divergence. In one case, this involved a loss of the p53 locus in the CD38 + fraction, a marker that was not observed in the parallel CD38 -fraction (Table 2 ). More generally, our observations point to the possibility of monitoring an aspect of the evolution of the disease that might have profound clinical significance. Within an overall apparently constant leukemic burden, the outgrowth of a subclone with additional genomic lesions might signal the start of a new phase of the disease. Additional studies, combining data on fractionated subpopulations with clinical outcomes, are needed to test this hypothesis.
In summary, we have demonstrated that ROMA is a highly sensitive CGH method to examine genomic changes in CLL. We have detected novel lesions, ascertained the frequencies of gains and losses with greater accuracy, and pinpointed candidate genes. The apparent continuing evolution of clones of CLL within a patient 
